(Q38028366)

27 August 2017

Rifampicin and Parkinson's disease (English)

1 reference

27 August 2017

1 reference

Wei Bi

1

1 reference

27 August 2017

Lihong Zhu

2

1 reference

27 August 2017

Xiuna Jing

3

1 reference

27 August 2017

Yanran Liang

4

1 reference

27 August 2017

Enxiang Tao

5

1 reference

27 August 2017

21 July 2012

1 reference

27 August 2017

Neurological Sciences

1 reference

27 August 2017

34

1 reference

27 August 2017

2

1 reference

27 August 2017

137-141

1 reference

https://scigraph.springernature.com/pub.10.1007/s10072-012-1156-0

27 August 2017

0 references

cites work

Parkinson's disease: current and future challenges

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Parkinson's: symptoms, treatments and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Molecular pathogenesis of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Epidemiology and etiology of Parkinson's disease: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

The pathogenesis of cell death in Parkinson's disease--2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Priorities in Parkinson's disease research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampicin attenuates brain damage in focal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

New hope for mechanism-based treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Alpha-synuclein and the pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

The role of alpha-synuclein in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

The rotenone model of Parkinson's disease: genes, environment and mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

The role of mitochondria in reactive oxygen species metabolism and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Role of mitochondria in toxic oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Parkinson's disease--redox mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Novel anti-inflammatory and neuroprotective agents for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Activation of microglial cells by beta-amyloid protein and interferon-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Molecular mechanisms of microglial activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampicin Inhibits the LPS-induced Expression of Toll-like Receptor 2 via the Suppression of NF-kappaB DNA-binding Activity in RAW 264.7 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-012-1156-0

Rifampin reduces production of reactive oxygen species of cerebrospinal fluid phagocytes and hippocampal neuronal apoptosis in experimental Streptococcus pneumoniae meningitis

21 January 2018

1 reference

12 December 2020

An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

1 reference

12 December 2020

[The anti-tubercular drugs in the treatment of psoriasis]

1 reference

12 December 2020

Practice pearl: a novel use of rifampicin for treatment of carpal tunnel syndrome

1 reference

12 December 2020

Mitochondrial Dysfunction in Parkinson's Disease

1 reference

12 December 2020

Effect of rifampin on the immune response in mice

1 reference

12 December 2020

Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease

1 reference

12 December 2020

alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease?

1 reference

12 December 2020

Biomarkers of cell damage induced by oxidative stress in Parkinson's disease and related models.

1 reference

12 December 2020

Decreased beta-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy

1 reference

12 December 2020

Targeting alpha-synuclein in Parkinson's disease

1 reference

12 December 2020

Neuropathology of Parkinson's disease

1 reference

12 December 2020

Parkinson's disease--challenges in new drug development

1 reference

12 December 2020

10.1007/S10072-012-1156-0

Identifiers

DOI

1 reference

27 August 2017

1 reference